HbA1c 5.7% — the 3-month window before diabetes
An HbA1c (glycated haemoglobin) of 5.7% sits exactly at the American Diabetes Association threshold for prediabetes and represents an estimated average glucose of approximately 117 mg/dL (6.5 mmol/L) over the past 8–12 weeks. The number captures non-enzymatic glycation of haemoglobin — sugar permanently bonded to red blood cells — and because RBC lifespan is ~120 days, it integrates glucose exposure over that whole window. A reading of 5.7 means your glucose has been chronically running above the 5.5% / 100 mg/dL average that the literature associates with optimal metabolic health, but you have not crossed the diabetic threshold (6.5%).
Reference ranges
| Optimal | < 5.0% |
| Normal | 5.0 – 5.6% |
| Prediabetic | 5.7 – 6.4% |
| Type 2 diabetic | ≥ 6.5% |
| Average glucose at HbA1c 5.7% | ~117 mg/dL (6.5 mmol/L) |
What this marker measures
HbA1c is the percentage of haemoglobin molecules that have undergone non-enzymatic glycation — i.e., have a glucose molecule covalently bonded to them. Because this reaction is essentially irreversible at physiological pH and red blood cells live ~4 months, HbA1c integrates glucose exposure across the entire RBC lifespan. The Diabetes Control and Complications Trial established its predictive value for microvascular complications, and it remains the gold-standard chronic glycaemia metric. It is unaffected by short-term meals or recent activity, which is both its strength (longitudinal honesty) and its limitation (slow to respond to intervention).
Why might it be elevated?
- ·Insulin resistance — by far the most common cause
- ·Visceral adiposity and metabolic syndrome
- ·High-frequency carbohydrate intake (snacking, sweetened drinks)
- ·Sedentary lifestyle reducing muscle glucose uptake
- ·Sleep deprivation — even one week shifts HbA1c trajectory
- ·Chronic cortisol elevation (stress, glucocorticoids)
- ·Iron deficiency (falsely raises HbA1c via prolonged RBC lifespan)
- ·Genetic predisposition (TCF7L2 variants)
Why might it be low?
- ·Haemolytic anaemia — shorter RBC lifespan reduces glycation time
- ·Recent blood loss or transfusion
- ·Chronic kidney disease in late stages
- ·Pregnancy (RBC turnover increases)
- ·Athletic training + low-carb diet pattern
FAQ
Will I become diabetic?+
The Diabetes Prevention Programme and other longitudinal cohorts show ~10–15% of prediabetic individuals progress to type 2 diabetes per year without intervention. With structured lifestyle change (~7% body weight loss + 150 min/week exercise), DPP showed 58% relative risk reduction — outperforming metformin in that trial.
How fast can HbA1c drop?+
Slowly. Because HbA1c integrates 8–12 weeks of glucose, even aggressive intervention takes 6–12 weeks to show meaningful change. A 0.3–0.5% drop in 12 weeks of consistent dietary + exercise change is typical. Don't retest before 8 weeks.
Is HbA1c 5.7% always real prediabetes?+
Not always — iron deficiency anaemia falsely elevates HbA1c. Cross-check with fasting glucose, fasting insulin, and HOMA-IR. If those are all normal, the HbA1c may be misleading. Conversely, athletic individuals on low-carb diets sometimes have low-normal HbA1c despite occasional glucose spikes — single-marker reads can mislead in either direction.
This page describes biomarker research and reference ranges for self-tracking and research-context discussion only. It is not medical advice, not a diagnosis, and not a substitute for a qualified physician. Take any concerns about your health to a clinician.
Have your own panel? Read it next to the standard reference ranges with our free analyse tool.
Analyse my blood work →- BiomarkerHOMA-IR 2.5
HOMA-IR is a calculated index from fasting glucose × fasting insulin. A HOMA-IR of 2.5 sits at the threshold most metabolic research uses for early insulin resistance, often years before HbA1c shifts.
- BiomarkerFasting glucose 100
Fasting glucose at 100 mg/dL (5.6 mmol/L) sits exactly at the ADA threshold for impaired fasting glucose. What it indicates, why it precedes HbA1c shifts, and the research-literature interpretation.
- BiomarkerFasting insulin 12
Fasting insulin of 12 µIU/mL is above the optimal threshold most metabolic research uses (~8). What it indicates, why doctors miss it, and the research literature on early insulin resistance.
- ResearchRetatrutide 40 mg pen
Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. The 40 mg pen is the highest-dose presentation in the Omega Grade catalogue
- ResearchCagrilintide 10 mg
Cagrilintide is a long-acting amylin analogue most widely investigated in combination with semaglutide under the CagriSema programme. Commonly stacked
- ResearchRetatrutide 30 mg kit
Retatrutide 30 mg lyophilised vial kit — the mid-dose research presentation. Includes bacteriostatic water, syringes, and swabs.